Published in Neurodegener Dis Manag on January 01, 2012
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. Neurology (2014) 1.01
Subjective memory complaints, cognitive performance, and psychological factors in healthy older adults. Am J Alzheimers Dis Other Demen (2013) 0.87
Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire. Alzheimers Res Ther (2015) 0.80
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Influence of education and occupation on the incidence of Alzheimer's disease. JAMA (1994) 8.43
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Midlife cardiovascular risk factors and risk of dementia in late life. Neurology (2005) 5.12
The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol (2000) 4.77
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging (2000) 4.22
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol (2008) 4.07
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA (1995) 3.39
Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol (2009) 3.35
Relation of cognitive activity to risk of developing Alzheimer disease. Neurology (2007) 3.34
Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2004) 3.26
Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc (2008) 3.21
Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study. Neurology (2005) 3.21
Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke (2002) 3.05
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology (2010) 2.92
The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry (1998) 2.91
Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology (1994) 2.84
Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol (2009) 2.83
Intelligent Systems For Assessing Aging Changes: home-based, unobtrusive, and continuous assessment of aging. J Gerontol B Psychol Sci Soc Sci (2011) 2.71
Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol (2011) 2.65
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Leisure activities and the risk of amnestic mild cognitive impairment in the elderly. Neurology (2006) 2.51
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology (2005) 2.45
The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA (1999) 2.42
White matter damage on diffusion tensor imaging correlates with age-related cognitive decline. Neurology (2006) 2.42
Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol (2002) 2.41
Neurodegenerative basis of age-related cognitive decline. Neurology (2010) 2.41
Pattern separation deficits associated with increased hippocampal CA3 and dentate gyrus activity in nondemented older adults. Hippocampus (2010) 2.39
Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement (2009) 2.38
Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis (2009) 2.34
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med (2010) 2.17
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol (2010) 2.15
Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry (1999) 2.14
Correlates of cognitive function in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Gerontology (1998) 2.07
Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry (2010) 2.04
Selective review of cognitive aging. J Int Neuropsychol Soc (2010) 1.97
Cerebral infarcts and cognitive performance: importance of location and number of infarcts. Stroke (2009) 1.93
Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc (2005) 1.90
Education delays accelerated decline on a memory test in persons who develop dementia. Neurology (2007) 1.87
Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology (2004) 1.87
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
White matter microstructural integrity and cognitive function in a general elderly population. Arch Gen Psychiatry (2009) 1.74
Integrating clinical assessment with cognitive neuroscience: construct validation of the California Verbal Learning Test. J Consult Clin Psychol (1988) 1.71
Education, the brain and dementia: neuroprotection or compensation? Brain (2010) 1.68
Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. Arch Neurol (2011) 1.68
Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology (1999) 1.67
Stroke and memory performance in elderly persons without dementia. Arch Neurol (2006) 1.65
Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol (2007) 1.61
Decomposing age correlations on neuropsychological and cognitive variables. J Int Neuropsychol Soc (2009) 1.61
Relationship of age, education, and occupation with dementia among a community-based sample of African Americans. Arch Neurol (1996) 1.55
Current and remote blood pressure and cognitive decline. JAMA (1999) 1.43
Prevalence and predictors of “subjective cognitive complaints” in the Sydney Memory and Ageing Study. Am J Geriatr Psychiatry (2010) 1.41
Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology (2009) 1.41
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain (2011) 1.41
Subjective memory complaints and awareness of memory functioning in mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord (2009) 1.39
The influence of education on clinically diagnosed dementia incidence and mortality data from the Kungsholmen Project. Arch Neurol (2001) 1.38
Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals. Neuropsychology (2004) 1.38
Visual short-term memory binding deficits in familial Alzheimer's disease. Brain (2010) 1.32
Subjective cognitive complaints and cognitive decline: consequence or predictor? The epidemiology of vascular aging study. J Am Geriatr Soc (2005) 1.31
Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology (1998) 1.24
Leisure activity and cognitive decline in incident Alzheimer disease. Arch Neurol (2007) 1.21
Memory complaints in nondemented men predict future pathologic diagnosis of Alzheimer disease. Neurology (2004) 1.19
Neuroimaging correlates of subjective memory deficits in a community population. Neurology (2008) 1.18
Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes. Neurology (2011) 1.13
Neuropsychological function in nondemented carriers of presenilin-1 mutations. Neurology (2005) 1.13
Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers. Neurology (2011) 1.09
Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers (2011) 1.06
Longitudinal neuroimaging correlates of subjective memory impairment: 4-year prospective community study. Br J Psychiatry (2011) 1.06
Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study. Genet Med (2006) 1.03
Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease. Alzheimer Dis Assoc Disord (2014) 1.03
Influence of myocardial infarction, coronary artery bypass surgery, and stroke on cognitive impairment in late life. Am J Cardiol (1998) 1.02
The measurement of everyday cognition: development and validation of a short form of the Everyday Cognition scales. Alzheimers Dement (2011) 1.01
Assessment of cognition in mild cognitive impairment: a comparative study. Alzheimers Dement (2011) 1.00
Effects of sex and APOE epsilon4 on object recognition and spatial navigation in the elderly. Neuroscience (2007) 0.99
The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet (2010) 0.98
Assessment of cognition in early dementia. Alzheimers Dement (2011) 0.94
Spoken Language Derived Measures for Detecting Mild Cognitive Impairment. IEEE Trans Audio Speech Lang Process (2011) 0.93
Intra-individual variability in Alzheimer's disease and cognitive aging: definitions, context, and effect sizes. PLoS One (2011) 0.93
Validity of the free and cued selective reminding test in predicting dementia: the 3C study. Neurology (2010) 0.92
Perceptions of familial risk in those seeking a genetic risk assessment for Alzheimer's disease. J Genet Couns (2008) 0.89
Effects of epsilon4 on object recognition in the non-demented elderly. Curr Aging Sci (2010) 0.77
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Common Kibra alleles are associated with human memory performance. Science (2006) 3.30
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain (2008) 1.82
Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol (2013) 1.75
Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry (2007) 1.68
Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry (2005) 1.63
Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis (2010) 1.54
Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol Aging (2013) 1.53
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Depressive symptoms in healthy apolipoprotein E ε4 carriers and noncarriers: a longitudinal study. J Clin Psychiatry (2013) 1.41
Hippocampal adaptation to face repetition in healthy elderly and mild cognitive impairment. Neuropsychologia (2004) 1.35
Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging (2012) 1.30
Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging (2011) 1.27
Regional network of magnetic resonance imaging gray matter volume in healthy aging. Neuroreport (2006) 1.27
Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet (2007) 1.24
Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging (2008) 1.24
Cognitive performance in older women relative to ApoE-epsilon4 genotype and aerobic fitness. Med Sci Sports Exerc (2007) 1.22
Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage (2009) 1.17
Linking functional and structural brain images with multivariate network analyses: a novel application of the partial least square method. Neuroimage (2009) 1.17
Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. Neurobiol Aging (2003) 1.10
Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing. Mitochondrion (2006) 1.07
Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol (2013) 1.03
Small-amplitude cortical myoclonus in Parkinson's disease: physiology and clinical observations. Mov Disord (2002) 1.02
Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol (2010) 1.02
Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen (2010) 1.01
Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord (2005) 1.01
Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults. Neurobiol Aging (2012) 1.00
Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiol Aging (2008) 1.00
Cognitive frailty: Predementia syndrome and vascular risk factors. Neurobiol Aging (2005) 0.99
Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathol (2014) 0.98
Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology (2013) 0.98
Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol (2003) 0.98
Depressive symptoms, vascular risk factors and mild cognitive impairment. The Italian longitudinal study on aging. Dement Geriatr Cogn Disord (2008) 0.96
Autoimmune encephalopathy. Semin Neurol (2011) 0.96
Temporal relationship between depressive symptoms and cognitive impairment: the Italian Longitudinal Study on Aging. J Alzheimers Dis (2009) 0.96
Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage (2008) 0.96
Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study. Hum Brain Mapp (2014) 0.96
A roadmap for improving healthcare service quality. J Healthc Manag (2011) 0.91
Disrupted daytime activity and altered sleep-wake patterns may predict transition to mild cognitive impairment or dementia: a critically appraised topic. Neurologist (2012) 0.90
Incident occurrence of depressive symptoms among patients with mild cognitive impairment - the Italian longitudinal study on aging. Dement Geriatr Cogn Disord (2007) 0.89
APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. Neurobiol Aging (2012) 0.88
Longitudinal tracking of FTLD: toward developing clinical trial methodology. Alzheimer Dis Assoc Disord (2007) 0.88
Assessment of patient and caregiver experiences of dementia-related symptoms: development of the Multidimensional Assessment of Neurodegenerative Symptoms questionnaire. Dement Geriatr Cogn Disord (2009) 0.86
Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers. Neuroimage (2010) 0.86
"Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases. Neurologist (2007) 0.86
Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases. J Neurosurg (2008) 0.86
Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers. J Clin Psychiatry (2009) 0.85
Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene Dose. PLoS One (2013) 0.84
Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients. Neurologist (2008) 0.84
Anxiety affects cognition differently in healthy apolipoprotein E ε4 homozygotes and non-carriers. J Neuropsychiatry Clin Neurosci (2011) 0.83
Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. Arch Neurol (2007) 0.83
Whole genome association analysis shows that ACE is a risk factor for Alzheimer's disease and fails to replicate most candidates from Meta-analysis. Int J Mol Epidemiol Genet (2009) 0.81
Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord (2013) 0.81
Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist (2009) 0.78
Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination. Arch Neurol (2011) 0.78
Physical activity level and future risk of mild cognitive impairment or dementia: a critically appraised topic. Neurologist (2015) 0.78
Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic. Neurologist (2011) 0.77
Autoimmune encephalopathy. Mayo Clin Proc (2010) 0.77
Myoclonus in Lewy body disorders. Adv Neurol (2002) 0.76
Obstructive sleep apnea, apolipoprotein E e4, and mild cognitive impairment. Sleep Med (2008) 0.76
Compensation and finance in neurology. Ann Neurol (2008) 0.75
Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease. Neurology (2014) 0.75
Correlates of quitting the Paced Auditory Serial Addition Test in cognitively normal older adults participating in a study of normal cognitive aging. J Clin Exp Neuropsychol (2011) 0.75
APOE varepsilon2 and presymptomatic stage Alzheimer disease: how much is not enough? Neurology (2010) 0.75
Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: a case series. Neurocase (2011) 0.75
January 16 highlight and commentary: subspecialization within somatosensory cortex. Neurology (2007) 0.75
Giant cell arteritis. Curr Pain Headache Rep (2006) 0.75
Lorazepam Challenge for Individuals at Varying Genetic Risk for Alzheimer Disease. Alzheimer Dis Assoc Disord (2017) 0.75
The (Mis)diagnosis of Creutzfeldt-Jakob Disease. Arch Neurol (2012) 0.75